Literature DB >> 15138623

Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease.

Enzo Emanuele1, Emmanouil Peros, Giuseppe A Scioli, Angela D'Angelo, Carlo Olivieri, Lorenza Montagna, Diego Geroldi.   

Abstract

Elevated level of osteoprotegerin (OPG), a pleiotropic cytokine involved in bone metabolism, has been associated with coronary heart disease and higher cardiovascular mortality. Because cardiovascular disorders are recognized risk factors for dementia, the study of OPG as a disease marker in vascular dementia (VaD) and Alzheimer's disease (AD) seemed worthy of investigation. OPG concentration was determined by ELISA in an Italian cohort consisting of 39 VaD patients, 36 AD patients, and 39 non-demented controls strictly matched for age and gender. Plasma OPG levels were positively related to age in both demented and non-demented persons. OPG concentrations were significantly higher in both VaD (median: 4.75 pmol/l; interquartile range: 3.42-6.85 pmol/l; P<0.0001) and AD (median: 4.02 pmol/l; interquartile range: 3.07-4.77 pmol/l; P=0.0278) compared to non-demented controls (median: 3.24 pmol/l, interquartile range: 2.70-3.98 pmol/l). After allowance for confounding factors (age, gender and APOE epsilon4 allele), plasma OPG levels remained independently associated with the presence of VaD (OR = 2.51; 95% CI 1.46-4.32; P=0.0009) and AD (OR = 2.17; 95% CI 1.18-3.99; P=0.0126). Our study demonstrates that OPG may be regarded as a novel biomarker of dementia in the Italian population. These results further support the hypothesis that vascular factors may not only play a role in the pathogenesis of VaD but also in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138623

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

1.  Circulating Dkk1 and TRAIL Are Associated With Cognitive Decline in Community-Dwelling, Older Adults With Cognitive Concerns.

Authors:  Ryan D Ross; Raj C Shah; Sue Leurgans; Teodoro Bottiglieri; Robert S Wilson; Dale Rick Sumner
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-11-10       Impact factor: 6.053

2.  Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study.

Authors:  A L Jefferson; J M Massaro; P A Wolf; S Seshadri; R Au; R S Vasan; M G Larson; J B Meigs; J F Keaney; I Lipinska; S Kathiresan; E J Benjamin; C DeCarli
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

3.  APPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner.

Authors:  Shun Cui; Fei Xiong; Yan Hong; Ji-Ung Jung; Xing-Sheng Li; Jian-Zhong Liu; Riqiang Yan; Lin Mei; Xu Feng; Wen-Cheng Xiong
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

4.  Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease.

Authors:  Christian Luckhaus; Bijan Mahabadi; Brigitte Grass-Kapanke; Michaela Jänner; Holger Willenberg; Marcus Jäger; Tillmann Supprian; Karin Fehsel
Journal:  J Neural Transm (Vienna)       Date:  2009-05-26       Impact factor: 3.575

5.  Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases.

Authors:  Todd E Golde; Victor M Miller
Journal:  Alzheimers Res Ther       Date:  2009-10-12       Impact factor: 6.982

6.  Associations of Bone Turnover Markers with Cognitive Function in Patients Undergoing Hemodialysis.

Authors:  Ping-Hsun Wu; Yi-Ting Lin; Cheng-Sheng Chen; Yi-Wen Chiu; Jer-Chia Tsai; Po-Lin Kuo; Ya-Ling Hsu; Östen Ljunggren; Bengt Fellström; Mei-Chuan Kuo
Journal:  Dis Markers       Date:  2020-04-21       Impact factor: 3.434

7.  Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies.

Authors:  Joni V Lindbohm; Nina Mars; Keenan A Walker; Archana Singh-Manoux; Gill Livingston; Eric J Brunner; Pyry N Sipilä; Kalle Saksela; Jane E Ferrie; Ruth C Lovering; Stephen A Williams; Aroon D Hingorani; Rebecca F Gottesman; Henrik Zetterberg; Mika Kivimäki
Journal:  Alzheimers Dement       Date:  2021-08-02       Impact factor: 16.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.